Quality of Life in Patients with Advanced NSCLC Treated in Second-or Third-Line with Nab-Paclitaxel plus Durvalumab: ABOUND. 2L+

Talbot, D.Govindan, R.Cobo, M.Ponce Aix, S.Postmus, P. E.Lewanski, C.Bennouna, J.Fischer, J.Juan-Vidal, O.Stewart, D.Ardizzoni, A.Bhore, R.Wolfsteiner, M.Reck, M.Morgensztern, D.Ong, T. J.2025-01-072025-01-072018-10-011556-0864https://hdl.handle.net/10668/27925enquality of lifedurvalumabnab-paclitaxelQuality of Life in Patients with Advanced NSCLC Treated in Second-or Third-Line with Nab-Paclitaxel plus Durvalumab: ABOUND. 2L+conference outputopen access10.1016/j.jtho.2018.08.6491556-1380http://www.jto.org/article/S1556086418316071/pdf454014501283